For some biotechs, AI isn’t just a tool; it’s their entire thesis.

As early-stage life sciences companies prepare for their next financing or partnership, intellectual property due diligence is often the first, and most consequential, checkpoint.

Why do some life sciences companies stall between Series B and IPO?

J.P.Morgan Asset & Wealth Management, one of the largest global investment managers, has announced it will stop using third‑party proxy advisory firms for U.S. proxy voting and will instead rely on a newly launched internal, AI‑powered platform, Proxy IQ, to manage all aspects of the voting process for more than 3,000 company annual meetings.

Transitioning from discovery to clinical development marks a defining moment for emerging biotech companies. It’s also a time to consider evolving your IP strategy from protecting ideas to protecting assets.

Publicly sharing clinical results can trigger a range of regulatory and compliance obligations, especially for companies approaching or already in the public markets.

For any life sciences company, a clinical data readout is more than a scientific milestone. It’s a corporate event that can influence investor sentiment and the broader perception of the program.

In this market, the founders who succeed are generally the ones anchored by a strong “why,” a deep sense of humility, and a willingness to take their medicine when reality demands it.

President Donald Trump issued an EO directing a government-wide response to enhance oversight of proxy advisory firms.

The venture market in Q3 2025 resists simple characterization. Secondary market transaction volume remained muted, yet premium pricing rose to 38% of deals.

Amid rapid technological advancements and regulatory uncertainty, navigating the life sciences ecosystem can be challenging.